In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an interesting takeaway from the JPMorgan conference yesterday. While there are already options for investors to invest directly in the diabetes space, one thing that caught his eye was a potential indirect diabetes play, in the form of Dynavax's hepatitis-B vaccine. While the vaccine is not yet approved, the CDC's Advisory Committee on Immunization Practices recommended in 2011 that all diabetes patients between the ages of 19 and 59 be vaccinated against hepatitis B, which could double or potentially triple Dynavax's existing market opportunity for the vaccine.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.
The article Is This Vaccine a Diabetes Play? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.